Elanco Animal Health (ELAN)

Currency in USD
17.70
-0.26(-1.45%)
Closed·
17.85+0.15(+0.85%)
·
ELAN Scorecard
Full Analysis
High shareholder yield
ELAN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.6618.00
52 wk Range
8.0218.09
Key Statistics
Prev. Close
17.96
Open
17.79
Day's Range
17.66-18
52 wk Range
8.02-18.09
Volume
4.01M
Average Volume (3m)
5.6M
1-Year Change
22.08%
Book Value / Share
13.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELAN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.18
Upside
+2.72%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

Elanco Animal Health News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Employees
9225

Elanco Animal Health SWOT Analysis


Pipeline Prowess
Explore Elanco's robust product lineup, featuring Zenrelia and C. Quattro, poised to revolutionize animal health treatments and drive market growth
Market Expansion
Delve into Elanco's strategic clinic network expansion and competitive pricing, enhancing market reach and accessibility for innovative products
Financial Outlook
Analysts project mid-single-digit organic revenue growth for Elanco in 2025, with price targets ranging from $19 to $22 per share
Industry Dynamics
Uncover the potential in the growing animal health market, driven by increasing pet ownership and livestock production, alongside regulatory challenges
Read full SWOT analysis

Elanco Animal Health Earnings Call Summary for Q2/2025

  • Q2 2025 revenue up 5% YoY to $1.24B, adjusted EPS of $0.26 beating $0.20 forecast; stock surged 15.66% pre-market
  • Organic constant currency growth of 8%, driven by 5% volume increase and 3% price rise in pet and farm animal segments
  • Full-year organic growth projected at 5-6%; adjusted EBITDA forecast $850M-$890M; adjusted EPS expected $0.85-$0.91
  • Net debt leverage ratio improved to 4.0x; debt reduction remains primary focus for cash utilization
  • Upcoming product launches, including Advantage collar and IL-31, expected to drive further growth
Last Updated: 07/08/2025, 17:28
Read Full Transcript

Compare ELAN to Peers and Sector

Metrics to compare
ELAN
Peers
Sector
Relationship
P/E Ratio
20.3x5.8x−0.6x
PEG Ratio
0.150.170.00
Price/Book
1.3x1.2x2.6x
Price / LTM Sales
2.0x1.7x3.3x
Upside (Analyst Target)
1.8%191.5%39.1%
Fair Value Upside
Unlock18.3%4.5%Unlock

Analyst Ratings

9 Buy
5 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 18.18
(+2.72% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
0.26 / 0.20
Revenue / Forecast
1.24B / 1.18B
EPS Revisions
Last 90 days

ELAN Income Statement

People Also Watch

247.13
AVAV
+0.19%
28.99
CNC
+1.76%
137.06
FI
+0.26%
141.58
CRCL
-5.15%

FAQ

What Stock Exchange Does Elanco Animal Health Trade On?

Elanco Animal Health is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Elanco Animal Health?

The stock symbol for Elanco Animal Health is "ELAN."

What Is the Elanco Animal Health Market Cap?

As of today, Elanco Animal Health market cap is 8.79B.

What Is Elanco Animal Health's Earnings Per Share (TTM)?

The Elanco Animal Health EPS (TTM) is 0.88.

When Is the Next Elanco Animal Health Earnings Date?

Elanco Animal Health will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is ELAN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Elanco Animal Health Stock Split?

Elanco Animal Health has split 0 times.

How Many Employees Does Elanco Animal Health Have?

Elanco Animal Health has 9225 employees.

What is the current trading status of Elanco Animal Health (ELAN)?

As of 19 Aug 2025, Elanco Animal Health (ELAN) is trading at a price of 17.70, with a previous close of 17.96. The stock has fluctuated within a day range of 17.66 to 18.00, while its 52-week range spans from 8.02 to 18.09.

What Is Elanco Animal Health (ELAN) Price Target According to Analysts?

The average 12-month price target for Elanco Animal Health is USD18.18182, with a high estimate of USD21 and a low estimate of USD14. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +2.72% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.